An eight-member panel voted unanimously against wider use of Pfizer’s Talzenna in advanced prostate cancer. Elsewhere, U.K.

In a somber end to an FDA advisory committee’s two-day scouring of multiple drugmakers’ oncology data, Pfizer’s pitch to ...

Talzenna is currently approved in combination with Xtandi (enzalutamide) for individuals with castration-resistant prostate ...

The U.S. Food and Drug Administration has approved Amneal Pharmaceuticals' self-administered migraine drug, giving way to a ...

Pfizer Inc.’s stock rose handily Tuesday after the drug manufacturer said it’s trending toward the higher end of its 2025 profit projections. Pfizer also beat analyst expectations for first ...

Pfizer's CEO said tariff uncertainty is hindering the company from making big investments in the US. Albery Bourla said there could be "tremendous investments" in R&D and manufacturing in the US ...

Global pharmaceutical company Pfizer Inc. is donating $750,000 to bolster tribal health care services in Oklahoma, with three Indigenous-operated clinics set to receive funding. The one-time ...

Altimmune and Viking Therapeutics have promising obesity drugs and could be great acquisition targets for Pfizer. Pfizer should be able to easily fund an acquisition of either small drugmaker.

After years of falling Covid treatment sales, lukewarm drug launches and a fizzled out weight-loss play, Pfizer is focusing on cost-cutting and reinvesting in new drug research in hopes that it ...

Both Pfizer and Viking aim to enter the high-growth weight loss drug market. Analysts forecast this market could be worth as much as $130 billion just a few years from now. Big pharmaceutical ...

David Denton; Executive Vice President, Chief Financial Officer; Pfizer Inc Aamir Malik; Executive Vice President, Chief US Commercial Officer; Pfizer Inc Alexandre De Germay; Executive Vice ...